Literature DB >> 7529932

Smallpox: emergence, global spread, and eradication.

F Fenner1.   

Abstract

Speculatively, it is suggested that variola virus, the cause of smallpox, evolved from an orthopoxvirus of animals of the central African rain forests (possibly now represented by Tatera poxvirus), some thousands of years ago, and first became established as a virus specific for human beings in the dense populations of the Nile valley perhaps five thousand years ago. By the end of the first millennium of the Christian era, it had spread to all the densely populated parts of the Eurasian continent and along the Mediterranean fringe of north Africa. It became established in Europe during the times of the Crusades. The great voyages of European colonization carried smallpox to the Americas and to Africa south of the Sahara. Transported across the Atlantic by Europeans and their African slaves, it played a major role in the conquest of Mexico and Peru and the European settlement of north America. Variolation, an effective preventive inoculation, was devised as early as the tenth century. In 1798 this practice was supplanted by Jenner's cowpox vaccine. In 1967, when the disease was still endemic in 31 countries and caused ten to fifteen million cases and about two million deaths annually, the World Health Organization embarked on a programme that was to see the disease eradicated globally just over ten years later, and the world was formally declared to be free of smallpox in May 1980. Smallpox is unique--a specifically human disease that emerged from some animal reservoir, spread to become a worldwide, severe and almost universal affliction, and finally underwent the reverse process to emergence, namely global eradication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7529932

Source DB:  PubMed          Journal:  Hist Philos Life Sci        ISSN: 0391-9714            Impact factor:   1.205


  21 in total

Review 1.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.

Authors:  Valeria M Zakharova; Michaela Serpi; Ivan S Krylov; Larryn W Peterson; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Mindy Collins; John M Hilfinger; Boris A Kashemirov; Charles E McKenna
Journal:  J Med Chem       Date:  2011-08-03       Impact factor: 7.446

3.  Comparative Biochemical and Functional Analysis of Viral and Human Secreted Tumor Necrosis Factor (TNF) Decoy Receptors.

Authors:  Sergio M Pontejo; Ali Alejo; Antonio Alcami
Journal:  J Biol Chem       Date:  2015-05-04       Impact factor: 5.157

4.  Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.

Authors:  Sharone Green; Francis A Ennis; Anuja Mathew
Journal:  Vaccine       Date:  2010-12-31       Impact factor: 3.641

5.  Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.

Authors:  Vidyashankara Iyer; Corinne Cayatte; Bernardo Guzman; Kirsten Schneider-Ohrum; Ryan Matuszak; Angie Snell; Gaurav Manohar Rajani; Michael P McCarthy; Bilikallahalli Muralidhara
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.

Authors:  Matthew P Bernard; Simona Bancos; Timothy J Chapman; Elizabeth P Ryan; John J Treanor; Robert C Rose; David J Topham; Richard P Phipps
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

7.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 8.  Understanding Immunity through the Lens of Disease Ecology.

Authors:  Stephen M Hedrick
Journal:  Trends Immunol       Date:  2017-09-04       Impact factor: 16.687

9.  Progression of pathogenic events in cynomolgus macaques infected with variola virus.

Authors:  Victoria Wahl-Jensen; Jennifer A Cann; Kathleen H Rubins; John W Huggins; Robert W Fisher; Anthony J Johnson; Fabian de Kok-Mercado; Thomas Larsen; Jo Lynne Raymond; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

Review 10.  Using cross-species vaccination approaches to counter emerging infectious diseases.

Authors:  George M Warimwe; Michael J Francis; Thomas A Bowden; Samuel M Thumbi; Bryan Charleston
Journal:  Nat Rev Immunol       Date:  2021-06-17       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.